EAU 2017: Reading and interpreting mpMRI: PIRADS 2.0
London, England (UroToday.com) Dr. Rooij gave a short and well organized presentation on the reading and interpretation of the PIRADS ver. 2. PI-RADS (Prostate Imaging Reporting and Data System) are the clinical guidelines for multiparametric MRI of the prostate to detect clinically significant prostate cancer.
EAU 2017: European Society of Urogenital Radiology (ESUR) lecture PI-RADS in clinical practice including differential diagnoses in prostate imaging
London, England (UroToday.com) In her presentation Dr. Theony, a radiologist from Berne, presented a short summary on PI-RADS implementation in clinical practice of prostate imaging. PI-RADS (Prostate Imaging Reporting and Data System) are the clinical guidelines for multiparametric MRI of the prostate to detect clinically significant prostate cancer.
EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy (804)
London, England (UroToday.com) Despite recent publicity regarding the results of the ProtecT trial, which demonstrated no difference in PCa-specific survival after a median of 10 yr follow-up (FU) between surgery (RP), radiotherapy (RT) and active monitoring (AM) in men with screen detected localized prostate cancer (PCa), the primary issue with the study remains that the active monitoring arm is significantly different than active surveillance.
EAU 2017: MRI as a follow up tool in active surveillance: results from an MRI-defined active surveillance cohort
London, England (UroToday.com) Active surveillance (AS) has become a mainstay of therapy for low-volume, low-risk prostate cancer, and in some institutions, it is also utilized for low-volume intermediate risk disease. However, the introduction of multiparametric MRI (mpMRI) has significantly changed our evaluation of the prostate, both in men with elevated PSA (undiagnosed prostate cancer) and in men on active surveillance.
EAU 2017: Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer
London, England (UroToday.com) As multiparametric MRI’s (mpMRIs) continue to gain traction in the evaluation and monitoring of prostate cancer, the possibility of replacing biopsy with MRI has been considered.
EAU 2017: Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?
London, England (UroToday.com) Active surveillance now represents a standard of care for low-risk, low-volume prostate cancer. However, when counseling patients, it is often cited that progression later during AS can be salvaged without any loss in curative potential. However, certain studies have identified discordances between pathology at the time of RP and biopsy pathology, which introduces concern for disease progression that is not identified on active surveillance.
EAU 2017: PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings
London, England (UroToday.com) The authors of this study attempt to identify a potential biomarker for clinical progression and survival in patients on active surveillance (AS) for low-risk, low-volume prostate cancer. Prior literature has demonstrated that protein expression of PTEN and ERG have been considered as potential biomarkers of PC progression and survival.